Nrx Pharmaceuticals, INC. (NRXPW) — 10-Q Filings

10-Q Filings (5)

• NRX Pharmaceuticals' Net Loss Widens Amidst R&D Shifts, Revenue Debut — Nov 14, 2025 Risk: high
  NRX Pharmaceuticals, Inc. (NRXP) reported a significant increase in net loss for the nine months ended September 30, 2025, reaching $28.98 million, up from $16.
• NRX Pharmaceuticals Q2 2025 Update: Revenue Flat, Assets Shift — Aug 18, 2025 Risk: medium
  NRX Pharmaceuticals, Inc. filed its 10-Q for the period ending June 30, 2025. The company reported $0.001 in revenue for the six months ended June 30, 2025, com
• NRX Pharmaceuticals Q1 2025: Minimal Revenue, Significant Cash — May 15, 2025 Risk: medium
  NRX Pharmaceuticals, Inc. filed a 10-Q for the period ending March 31, 2025. The company reported $0.001 in revenue for the quarter. As of March 31, 2025, NRX P
• NRX Pharmaceuticals Files 10-Q, Details Stock Changes — Aug 14, 2024 Risk: medium
  NRX Pharmaceuticals, Inc. filed its 10-Q for the period ending June 30, 2024. The company reported significant changes in its capital structure, including an in
• NRX Pharmaceuticals, Inc. Files 10-Q for Period Ending March 31, 2024 — May 14, 2024 Risk: medium
  NRX Pharmaceuticals, Inc. (NRXPW) filed a Quarterly Report (10-Q) with the SEC on May 14, 2024. NRX Pharmaceuticals, Inc. filed a 10-Q report for the period end

Popular Companies

AAPL · TSLA · MSFT · AMZN · GOOGL · META · NVDA · JPM · BRK-B · V · JNJ · UNH · XOM · WMT · MA · PG · HD · DIS · BAC · NFLX